Regenxbio Inc. thinks it could grab a sizable portion of a crowded market for retinal diseases that stands to grow significantly over the next several years with interim Phase II data showing relative stability in best corrected visual acuity (BCVA) and central retinal thickness (CRT) among patients with wet age-related macular degeneration receiving ABBV-RGX-314, the gene therapy it is developing with AbbVie Inc. for retinal diseases. However, Regenxbio is remaining mum about exact plans for its pivotal Phase III trial.
Regenxbio Aims For Big Chunk Of Retinal Disease Market With AbbVie-Partnered Gene Therapy
The company presented promising Phase II data, but it didn’t reveal its plans for a pivotal trial of ABBV-RGX-314, which would compete in a growing – but increasingly crowded – market.
